Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer

BACKGROUND: Modified fluorouracil/leucovorin/irinotecan/oxaliplatin (FOLFIRINOX) regimen (mFOLFIRINOX), comprised of fluorouracil, leucovorin, irinotecan and oxaliplatin, is the first-line standard chemotherapy in patients with advanced pancreatic cancer. The S-1/oxaliplatin/irinotecan (SOXIRI) regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xujia, Huang, Jinsheng, Wang, Fenghua, Jiang, Qi, Huang, Lingli, Li, Shengping, Guo, Guifang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331348/
https://www.ncbi.nlm.nih.gov/pubmed/37435561
http://dx.doi.org/10.1177/17588359231186029

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331348/
https://www.ncbi.nlm.nih.gov/pubmed/37435561
http://dx.doi.org/10.1177/17588359231186029

Ejemplares similares